This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Anavex Invited To File Funding Application For Phase 2a Clinical Trial Of ANAVEX 2-73

VANCOUVER, May 6, 2013 /PRNewswire/ - Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) today announced that it has been invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation ("ADDF") for a Phase 2a trial of ANAVEX 2-73.  Since 1998, the ADDF has granted more than $51 million in venture philanthropy funding to projects with potential viability in the market. Subsequent to the ADDF's initial funding, grantees have received commitments of over $2 billion in follow-on funding from government, pharmaceutical companies and venture capital firms to further advance their drugs.

"We are excited by this invitation to submit a funding application for a Phase 2a trial of ANAVEX 2-73," said Tom Skarpelos, director of Anavex.  "The data generated for ANAVEX 2-73 to date indicates that it has the potential to prevent, halt and/or reverse the course of Alzheimer's disease, which could improve the lives of millions of Americans."

In pre-clinical studies, ANAVEX2-73 demonstrated cognitive benefit, the ability to protect neurons to prevent cell death, and a clear synergic effect with Aricept® (donepezil HCl), a leading, FDA-approved Alzheimer's treatment.  A Phase 1 human clinical trial of ANAVEX 2-73 has also been successfully completed.

The objective of the proposed Phase 2a clinical trial is to demonstrate objective biomarker data that can be correlated to clinical findings.  It would also seek to confirm the pre-clinical synergy observed when combining ANAVEX 2-73 with donepezil in patients with Alzheimer's disease.  Data generated would help determine the decision to proceed to a larger Phase 2 trial.

The invitation to submit a full application was received following the filing by Anavex of a Letter of Intent for a grant titled, "Clinical phase 2a study of ANAVEX 2-73 in patients using FDG-PET imaging as a functional biomarker."  Anavex now intends to file a full application with the ADDF.  There can be no assurance that the Company's application for a grant from the ADDF will be approved.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs